Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019
Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019
SUMMARY
Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 16 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019, outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Pancreatic Cancer, Malignant Glioma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Leukemia, Lung Cancer, Melanoma, Solid Tumor, Adrenal Gland Cancer, Breast Cancer, Colorectal Cancer, Essential Thrombocythemia, Fallopian Tube Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycythemia Vera, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, Testicular Cancer, Thrombocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 16 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019, outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Pancreatic Cancer, Malignant Glioma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Leukemia, Lung Cancer, Melanoma, Solid Tumor, Adrenal Gland Cancer, Breast Cancer, Colorectal Cancer, Essential Thrombocythemia, Fallopian Tube Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycythemia Vera, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, Testicular Cancer, Thrombocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)
- The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Wilms Tumor Protein (WT33 or WT1) - Overview
Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development
Cue Biopharma Inc
Inovio Pharmaceuticals Inc
Scancell Holdings Plc
SELLAS Life Sciences Group Inc
Sumitomo Dainippon Pharma Co Ltd
tella Inc
Vaximm AG
Wilms Tumor Protein (WT33 or WT1) - Drug Profiles
Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galinpepimut-S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ombipepimut-s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLP-0001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXM-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Wilms Tumor Protein (WT33 or WT1) - Dormant Products
Wilms Tumor Protein (WT33 or WT1) - Discontinued Products
Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: Boston Biomedical highlights phase 1 data evaluating investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) in patients with advanced malignancies at SITC 2019
Nov 08, 2019: SELLAS to host R&D investor event on Galinpepimut-S (GPS) and the next generation of cancer immunotherapy
Nov 05, 2019: Inovio demonstrates 80% 6-month progression-free survival in phase 2 Glioblastoma Multiforme (GBM) study with INO-5401 in combination with PD-1 inhibitor Libtayo (cemiplimab)
Jul 31, 2019: SELLAS advances Galinpepimut-S (GPS) in combination with KEYTRUDA (pembrolizumab) program with dosing of first patient in phase 1/2 basket study
Apr 04, 2019: SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)
Apr 03, 2019: Inovio closes enrolment in Phase I/II glioblastoma trial
Feb 12, 2019: SELLAS Life Sciences provides Galinpepimut-S program update
Jan 29, 2019: John Theurer Cancer Center leading enrollment for global phase 2 WIZARD study evaluating DSP-7888 in patients with recurrent glioblastoma
Jan 08, 2019: SELLAS Life Sciences provides update on Galinpepimut-S (GPS)
Dec 20, 2018: Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT Target in Oncology
Nov 28, 2018: SELLAS Life Sciences announces expedited development path for Galinpepimut-S (GPS) in acute myeloid leukemia (AML) following feedback from FDA
Sep 13, 2018: SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
Jul 20, 2018: SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Wilms Tumor Protein (WT33 or WT1) - Overview
Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development
Cue Biopharma Inc
Inovio Pharmaceuticals Inc
Scancell Holdings Plc
SELLAS Life Sciences Group Inc
Sumitomo Dainippon Pharma Co Ltd
tella Inc
Vaximm AG
Wilms Tumor Protein (WT33 or WT1) - Drug Profiles
Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galinpepimut-S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ombipepimut-s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLP-0001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXM-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Wilms Tumor Protein (WT33 or WT1) - Dormant Products
Wilms Tumor Protein (WT33 or WT1) - Discontinued Products
Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: Boston Biomedical highlights phase 1 data evaluating investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) in patients with advanced malignancies at SITC 2019
Nov 08, 2019: SELLAS to host R&D investor event on Galinpepimut-S (GPS) and the next generation of cancer immunotherapy
Nov 05, 2019: Inovio demonstrates 80% 6-month progression-free survival in phase 2 Glioblastoma Multiforme (GBM) study with INO-5401 in combination with PD-1 inhibitor Libtayo (cemiplimab)
Jul 31, 2019: SELLAS advances Galinpepimut-S (GPS) in combination with KEYTRUDA (pembrolizumab) program with dosing of first patient in phase 1/2 basket study
Apr 04, 2019: SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)
Apr 03, 2019: Inovio closes enrolment in Phase I/II glioblastoma trial
Feb 12, 2019: SELLAS Life Sciences provides Galinpepimut-S program update
Jan 29, 2019: John Theurer Cancer Center leading enrollment for global phase 2 WIZARD study evaluating DSP-7888 in patients with recurrent glioblastoma
Jan 08, 2019: SELLAS Life Sciences provides update on Galinpepimut-S (GPS)
Dec 20, 2018: Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT Target in Oncology
Nov 28, 2018: SELLAS Life Sciences announces expedited development path for Galinpepimut-S (GPS) in acute myeloid leukemia (AML) following feedback from FDA
Sep 13, 2018: SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
Jul 20, 2018: SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Cue Biopharma Inc, H2 2019
Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Pipeline by Scancell Holdings Plc, H2 2019
Pipeline by SELLAS Life Sciences Group Inc, H2 2019
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
Pipeline by tella Inc, H2 2019
Pipeline by Vaximm AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Cue Biopharma Inc, H2 2019
Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Pipeline by Scancell Holdings Plc, H2 2019
Pipeline by SELLAS Life Sciences Group Inc, H2 2019
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
Pipeline by tella Inc, H2 2019
Pipeline by Vaximm AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Cue Biopharma Inc
Inovio Pharmaceuticals Inc
Scancell Holdings Plc
SELLAS Life Sciences Group Inc
Sumitomo Dainippon Pharma Co Ltd
tella Inc
Vaximm AG
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Cue Biopharma Inc
Inovio Pharmaceuticals Inc
Scancell Holdings Plc
SELLAS Life Sciences Group Inc
Sumitomo Dainippon Pharma Co Ltd
tella Inc
Vaximm AG
